Fig 7.

Transduction from several serotypes of rAAV after As₂O₃ treatment. Five- to 6-week-old C57BL/6 mice were treated for 5 days with 5 μg/g/day As₂O₃ or a PBS vehicle control by intraperitoneal injection and transduced with 1 × 10¹¹ vg rAAV6-CBA-luciferase (A and B), rAAV8-CBA-luciferase (C and D), or rAAV9-CBA-luciferase (E, F, G, and H) on the third day of treatment. Images from live luciferase imaging are shown on day 7 for rAAV6 (A) (5 min of exposure), day 2 for rAAV8 (C) (5 min of exposure), day 5 for rAAV9 (E) (1 min of exposure), and day 21 for rAAV9 (G) (1 min of exposure). Quantification of luciferase activity from live imaging is shown at the same time points for rAAV6 (B) (n = 4), rAAV8 (D) (n = 4), and rAAV9 (F and H) (n = 3). Error bars represent one SD. *, P < 0.05 based on the Kruskal-Wallis test.